These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20538617)

  • 1. On or off target: mutations, models, and predictions.
    Garraway LA; Hahn WC
    Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV; Robertson GP
    Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
    Nickoloff BJ; Vande Woude G
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-Raf kinase inhibitors for cancer treatment.
    Li N; Batt D; Warmuth M
    Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
    Whittaker S; Kirk R; Hayward R; Zambon A; Viros A; Cantarino N; Affolter A; Nourry A; Niculescu-Duvaz D; Springer C; Marais R
    Sci Transl Med; 2010 Jun; 2(35):35ra41. PubMed ID: 20538618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 8. A new BRAF inhibitor breaks resistance barriers.
    Scotece M; Drosten M
    Trends Cancer; 2024 Jul; 10(7):576-578. PubMed ID: 38866669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.
    Pritchard AL; Hayward NK
    Clin Cancer Res; 2013 May; 19(9):2301-9. PubMed ID: 23406774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.
    Lai F; Jin L; Gallagher S; Mijatov B; Zhang XD; Hersey P
    Adv Pharmacol; 2012; 65():27-43. PubMed ID: 22959022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.
    Rebecca VW; Smalley KS
    Expert Opin Investig Drugs; 2011 Feb; 20(2):137-40. PubMed ID: 21235427
    [No Abstract]   [Full Text] [Related]  

  • 13. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
    Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J
    J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug discovery: inhibitors that activate.
    Cichowski K; Jänne PA
    Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
    [No Abstract]   [Full Text] [Related]  

  • 17. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation and location important in cancer treatment.
    Lewis R
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321213
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug resistance, epigenetics, and tumor cell heterogeneity.
    Hoey T
    Sci Transl Med; 2010 Apr; 2(28):28ps19. PubMed ID: 20410528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SRC as a potential therapeutic target in solid tumor oncology.
    Gallick GE
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.